Key Highlights
- Capricor (NASDAQ:CAPR) fell 7.86% to USD 9.44 on November 13, 2026, with a Market Value of about USD 548 million and a 52-week range of USD 2.96 to USD 40.37.
- The FDA's target action date for deramiocel, a cell therapy for cardiomyopathy and muscle weakness in Duchenne muscular dystrophy, is November 22, 2026.
- An August amendment narrowed the requested label to upper limb Impairment in patients older than 9, and the review was extended by three months as a result.
- The third-quarter net loss widened to USD 42.7 million, or USD 0.73 per share, and cash and investments fell to about USD 198.5 million from USD 318.1 million at the end of 2025.
The Decision and the Narrower Label
Capricor (NASDAQ:CAPR) is a single-product story heading into a binary event. Deramiocel is a cell therapy derived from heart tissue, and the company is seeking approval to treat patients with Duchenne muscular dystrophy. The application has had a difficult path. An outside advisory committee voted against it in July, and in August the company submitted a major amendment that rebuilt its data package around a narrower population: patients older than 9 with impairment of the arms and hands. The FDA extended its review by three months, setting November 22 as the new target date. A July inspection of a clinical site resulted in a form listing one observation, to which the company says it has responded. The narrower label, if approved, would cover fewer patients than originally planned, which affects the size of the launch. The 52-week range of USD 2.96 to USD 40.37 shows how far sentiment has swung on each regulatory update.
Spending Ahead of a Launch
The company is spending as if approval is possible. Operating expenses rose to USD 44.7 million in the third quarter from USD 26.3 million, with research costs up to USD 29.6 million and general and administrative costs up to USD 15.1 million as pre-launch preparation continued. There was no Revenue in the quarter or the first nine months. Over nine months the net loss was USD 117.3 million. The loss of USD 0.73 per share was wider than the roughly USD 0.61 the market expected. The company says its cash will fund operations for at least the next twelve months, a shorter statement than earlier guidance, and it did not sell any shares through its at-the-market program this year through November 10. About 10% of the workforce was cut during the quarter. The screen's 46.97% change in Earnings Per Share does not reflect the widening loss in recent quarters.
What Happens Next
An approval would allow Capricor to begin selling deramiocel, though Manufacturing scale-up remains a constraint, with cleanroom validation planned for the first half of 2027. A rejection or a request for more data would likely send the shares sharply lower and could force cost cuts or new financing. Separately, an arbitration with its Japanese commercial partner is expected to begin in mid-2027, adding uncertainty over how the Economics of a US launch are shared. For Capricor (NASDAQ:CAPR), investors should prepare for a large move on or around November 22, and then watch the label wording, launch timing and any update to the cash runway. The 7.86% drop on November 13 shows how nervous the market is ahead of the decision. Approval would make deramiocel one of very few treatments aimed at the heart and skeletal muscle damage that shortens life in this disease.
Where Things Stand
Capricor (NASDAQ:CAPR) faces an FDA decision on deramiocel on November 22, 2026, for a narrower label than first sought, after a negative advisory vote in July. Cash of about USD 198.5 million funds at least twelve months. The decision will likely set the stock's direction for months.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...